Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Winderlich MarkOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,000Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Winderlich MarkOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:250,000Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Kandera ReinhardOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:406,200Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Orlinger KlausOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:367,300Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Aldag JornOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:971,400Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Necina RomanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:367,300Price:--
-
Dec 22, 2023 (filed on Dec 22, 2023)Insider Name:Gilead Sciences, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Aug 21, 2023 (filed on Aug 22, 2023)Insider Name:Kandera ReinhardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:7,000Price:$0.73
-
Aug 16, 2023 (filed on Aug 17, 2023)Insider Name:Kandera ReinhardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:8,000Price:$0.71
-
Jul 11, 2023 (filed on Jul 11, 2023)Insider Name:Aldag JornOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:5,000Price:$0.83
Filings by filing date
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Winderlich MarkOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,000Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Winderlich MarkOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:250,000Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Kandera ReinhardOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:406,200Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Orlinger KlausOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:367,300Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Aldag JornOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:971,400Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Necina RomanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:367,300Price:--
-
Dec 22, 2023 (filed on Dec 22, 2023)Insider Name:Gilead Sciences, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Aug 21, 2023 (filed on Aug 22, 2023)Insider Name:Kandera ReinhardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:7,000Price:$0.73
-
Aug 16, 2023 (filed on Aug 17, 2023)Insider Name:Kandera ReinhardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:8,000Price:$0.71
-
Jul 11, 2023 (filed on Jul 11, 2023)Insider Name:Aldag JornOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:5,000Price:$0.83
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 350 Fifth Avenue, 72Nd Floor, Suite 7240 NEW YORK NY 10118 |
Tel: | N/A |
Website: | https://www.hookipapharma.com |
IR: | See website |
Key People | ||
Joern Aldag Chief Executive Officer, Director | Reinhard Kandera Chief Financial Officer, Director | Roman Necina Chief Operating Officer |
Klaus Orlinger Chief Scientific Officer | Mark Winderlich Chief Development Officer |
Business Overview |
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company's replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc. |
Financial Overview |
For the fiscal year ended 31 December 2023, Hookipa Pharma Inc revenues increased 41% to $20.1M. Net loss increased 26% to $81.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 29% to $84.2M (expense), General and administrative - Balancing v increase of 9% to $16.9M (expense). |
Employees: | 151 as of Feb 29, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $20.13M as of Dec 31, 2023 |
EBITDA (TTM): | -$81.38M as of Dec 31, 2023 |
Net annual income (TTM): | -$81.58M as of Dec 31, 2023 |
Free cash flow (TTM): | -$61.68M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 98,950,107 as of Mar 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |